Keith Murphy
CEO & Founder Viscient Biosciences
Seminars
Wednesday 16th September 2026
Panel Discussion: Balancing Differentiation, Combination Strategies & Commercial Reality to Define the Next Generation of Successful MASH Therapies
4:10 pm
- Evaluating how developers can differentiate new therapies within an increasingly competitive landscape to demonstrate meaningful clinical value, enabling stronger positioning and improving future adoption
- Assessing when combination approaches are likely to provide the greatest therapeutic advantage over monotherapy strategies, improving development prioritization and maximizing long-term patient benefit
- Defining the clinical, regulatory and commercial attributes required for future therapies to succeed beyond initial approval, strengthening development decision-making and supporting long-term market impact
Wednesday 16th September 2026
Developing MASH Therapeutics Utilizing Complex 3D Human In Vitro, In Vivo & Ex Vivo Models to Validate MASH Therapeutic Efficacy Across Systems
12:00 pm
- Identification and validation of targets in complex 3d in vitro human models of MASH
- Comparison of activity throughout development across the development cycle, and the value of complex 3D human cellular in vitro models to reduce translational risk
- Integrating human-relevant ex vivo systems into validation and drug development workflows to increase biological relevance, improving decision-making and accelerating candidate progression
